Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | TTR | P02766 | 4/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18304525 | 1.00 | NPC1 (0.54) | NPC1MTORLCKTTRMMP1 | |
| SCHEMBL18304404 | 0.81 | ALDH1A1 (0.44) | NPC1MTORTTRMAOBGAA | |
| SCHEMBL18304402 | 0.81 | ALDH1A1 (0.44) | NPC1MTORTTRMAOBGAA | |
| SCHEMBL8967713 | 0.79 | LCK (0.67) | LCKMMP1MMP2MMP9MAOB | |
| SCHEMBL8967718 | 0.79 | LCK (0.67) | LCKMMP1MMP2MMP9MAOB | |
| SCHEMBL16805416 | 0.79 | NPC1 (0.45) | NPC1MTORTTRAPP | |
| SCHEMBL4701093 | 0.78 | LCK (0.64) | LCKMMP1MMP2MMP9MAOB | |
| SCHEMBL4701094 | 0.78 | LCK (0.64) | LCKMMP1MMP2MMP9MAOB | |
| SCHEMBL18304485 | 0.78 | MAOA (0.47) | NPC1MTORMAOB | |
| SCHEMBL18304487 | 0.78 | MAOA (0.47) | NPC1MTORMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2020-04-16 | — | — | US | disclosed |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | Basilea Pharmaceutica International AG (CH) | 2019-11-05 | — | — | US | disclosed |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-06-28 | — | — | US | disclosed |
| EP-3307725-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198691-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | BASILEA PHARMACEUTICA AG (CH) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | NPC1 52/4885MTOR 2496/4885LCK 4869/4885 |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | ABCB11, ABCC1, ABCC3 | NPC1 51/4885MTOR 2498/4885LCK 4871/4885 |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | NPC1 51/4885MTOR 2498/4885LCK 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.